Assessing the REsponse Rate of Weekly Neo-adjuvanT pacliTAxel (Taxol) in Nigerian Women With Breast Cancer (ARETTA)
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 10 Sep 2018
At a glance
- Drugs Paclitaxel (Primary) ; Carboplatin; Cyclophosphamide; Epirubicin; Fluorouracil; Gonadotropin releasing hormone; Letrozole; Pertuzumab; Tamoxifen; Trastuzumab
- Indications Advanced breast cancer; Carcinoma; Early breast cancer
- Focus Therapeutic Use
- Acronyms ARETTA
- 31 Aug 2018 Biomarkers information updated
- 30 Aug 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 06 Feb 2018 Planned initiation date changed from 1 Nov 2017 to 1 Nov 2018.